Endometrial ablation method

Information

  • Patent Grant
  • 12070263
  • Patent Number
    12,070,263
  • Date Filed
    Thursday, January 14, 2021
    4 years ago
  • Date Issued
    Tuesday, August 27, 2024
    4 months ago
Abstract
Systems and methods for endometrial ablation. The systems include a handle and elongated introducer sleeve extending to an expandable working end having a fluid-tight interior chamber. A thin dielectric wall surrounds at least a portion of the interior chamber and has an external surface for contacting endometrial tissue. The thin dielectric wall surrounds a collapsible-expandable frame and receives an electrically non-conductive gas. First and second polarity electrodes are exposed to the interior and exterior of the chamber, respectively. A radiofrequency power source operatively connects to the electrode arrangement to apply a radiofrequency voltage across the first and second electrodes, wherein the voltage is sufficient to initiate ionization of the neutral gas into a conductive plasma within the interior chamber, and to capacitively couple the current in the plasma across the thin dielectric wall to ablate endometrial tissue engaged by the external surface of the dielectric structure.
Description
BACKGROUND OF THE INVENTION
1. Field of the Invention

The present invention relates to electrosurgical methods and devices for global endometrial ablation in a treatment of menorrhagia. More particularly, the present invention relates to applying radiofrequency current to endometrial tissue by means of capacitively coupling the current through an expandable, thin-wall dielectric member enclosing an ionized gas.


A variety of devices have been developed or proposed for endometrial ablation. Of relevance to the present invention, a variety of radiofrequency ablation devices have been proposed including solid electrodes, balloon electrodes, metallized fabric electrodes, and the like. While often effective, many of the prior electrode designs have suffered from one or more deficiencies, such as relatively slow treatment times, incomplete treatments, non-uniform ablation depths, and risk of injury to adjacent organs.


For these reasons, it would be desirable to provide systems and methods that allow for endometrial ablation using radiofrequency current which is rapid, provides for controlled ablation depth and which reduce the risk of injury to adjacent organs. At least some of these objectives will be met by the invention described herein.


2. Description of the Background Art

U.S. Pat. Nos. 5,769,880; 6,296,639; 6,663,626; and 6,813,520 describe intrauterine ablation devices formed from a permeable mesh defining electrodes for the application of radiofrequency energy to ablate uterine tissue. U.S. Pat. No. 4,979,948 describes a balloon filled with an electrolyte solution for applying radiofrequency current to a mucosal layer via capacitive coupling. US 2008/097425, having common inventorship with the present application, describes delivering a pressurized flow of a liquid medium which carries a radiofrequency current to tissue, where the liquid is ignited into a plasma as it passes through flow orifices. U.S. Pat. No. 5,891,134 describes a radiofrequency heater within an enclosed balloon. U.S. Pat. No. 6,041,260 describes radiofrequency electrodes distributed over the exterior surface of a balloon which is inflated in a body cavity to be treated. U.S. Pat. No. 7,371,231 and US 2009/054892 describe a conductive balloon having an exterior surface which acts as an electrode for performing endometrial ablation. U.S. Pat. No. 5,191,883 describes bipolar heating of a medium within a balloon for thermal ablation. U.S. Pat. Nos. 6,736,811 and 5,925,038 show an inflatable conductive electrode.


BRIEF SUMMARY OF THE INVENTION

The present invention provides a systems and methods for endometrial ablation, which relate to method and apparatus disclosed in U.S. application Ser. No. 12/541,043; filed Aug. 13, 2009 and U.S. application Ser. No. 12/541,050 both filed on Aug. 13, 2009, the full disclosures of which are incorporated herein by reference. The systems for delivering radiofrequency current to tissue comprises a handle and elongated introducer sleeve extending to an expandable working end having a fluid-tight interior chamber. A thin dielectric wall surrounds at least a portion of the interior chamber and has an external surface for contacting endometrial tissue. The thin dielectric wall surrounds a collapsible-expandable frame. A gas inflow lumen and a gas outflow lumen are provided to communicate with the interior chamber for delivering a flow of an electrically non-conductive gas into and through the chamber. A first polarity electrode is provided which has a surface exposed to the interior chamber. A second polarity electrode exterior of the interior chamber is also provided that includes a surface adapted to contact body tissue. The system further includes a radiofrequency power source operatively connected to the electrode arrangement to apply a radiofrequency voltage across the first and second electrodes, wherein the voltage is sufficient to initiate ionization of the neutral gas into a conductive plasma within the interior chamber. The voltage further is sufficient to capacitively couple the current in the plasma across the thin dielectric wall and into endometrial tissue engaged by the external surface of the dielectric structure. The treatment method generally comprises delivering a radiofrequency current to endometrial tissue in order to heat and usually ablate the tissue to a desired depth, ranging from about 2 to 6 mm.


In one embodiment, the thin dielectric wall can comprise a conformable material, typically a silicone. A conformable dielectric wall can have a thickness in the range from about 0.005″ to 0.020″, usually from 0.008″ to 0.010″. The conformable wall may be non-distensible or may be elastic so that the wall structure may be expanded. For either non-distensible or elastic dielectric walls, the device may further comprise a frame which supports the conformable material, usually where the frame can be expanded and contracted to open and close the dielectric wall.


The hand-held device of the invention typically comprises a probe with an elongated introducer sleeve and a handle for actuating the collapsible-expandable frame to expand the thin dielectric wall in a uterine cavity. The introducer sleeve typically has a bore therein to house the thin-wall dielectric structure as the sleeve is introduced into the uterine cavity. The system further includes a controller for controlling the circulation of gas in a continuous flow through the interior chamber.


The radiofrequency power source is of the type used in electrosurgery, and will typically be configured to deliver a voltage in the range from 500 V (rms) to 2500 V (rms), usually from 600 V (rms) to 1200V (rms), typically at a current in the range from 0.1 A to 1 A, typically from 0.2 A to 0.5 A, and at a frequency in the range from 450 kHz to 550 kHz, usually from 480 kHz to 500 kHz.


The electrically non-conductive gas that is provided in a gas flow through the interior chamber can be provided from a disposable compressed gas cartridge. The flow rate of a non-conductive gas, such as argon, will typically be in the range from about 5 ml/sec to 50 ml/sec, preferably from 10 ml/sec to 30 ml/sec.


In accordance with embodiments, a method of endometrial ablation is provided, including expanding an expandable member in a patient uterus to contact endometrial tissue, the expandable member comprising a dielectric wall surrounding an interior chamber; containing a conductive plasma in the interior chamber of the expandable member; and applying a radiofrequency voltage across the plasma sufficient to capacitively couple current across the dielectric wall to ablate endometrial tissue.


In embodiments, containing the conductive plasma comprises converting a neutral gas into the conductive plasma. Converting the neutral gas into the conductive plasma may comprise applying the radiofrequency voltage across the neutral gas and providing a flow of the neutral gas to the interior chamber. Converting the neutral gas into the conductive plasma can include flowing at least one of the neutral gas and the plasma out of the interior chamber, as an example. The flow rate of the neutral gas may be, for example, within the range from 0.05 ml/sec to 50 ml/sec. The neutral gas may be a noble gas.


In embodiments, applying the radiofrequency voltage across the neutral gas may occur between a first electrode surface in the interior chamber and a second electrode surface external of the interior chamber.


In embodiments, expanding an expandable member comprises expanding the expandable member with a frame, the frame supporting at least a portion of the dielectric wall.


In embodiments, the method may comprise modulating RF energy delivery in response to a signal provided by a temperature sensor within the interior chamber. RF energy delivery may also be modulated based on a signal provided by a temperature sensor external of the interior chamber.


In further embodiments, a method of endometrial ablation is provided, including positioning a thin wall dielectric structure in a patient uterus to contact endometrial tissue; containing a conductive plasma in an interior chamber of the dielectric structure; and applying a radiofrequency voltage across the plasma sufficient to capacitively couple current across the dielectric wall to ablate endometrial tissue. The radiofrequency voltage may be sufficient to raise, for example, endometrial tissue to a temperature greater than 45 degrees Celsius for a time sufficient to ablate tissue to a depth of at least 1 mm.


In embodiments, applying voltage comprises providing a first electrode in the interior chamber and a second electrode coupled to patient tissue, and applying a voltage across the first and second electrodes.


In still more embodiments, a method of endometrial ablation is provided, comprising expanding a thin wall dielectric structure in a uterus to engage endometrial tissue; introducing an ionized gas into an interior chamber of the dielectric structure; and applying a radiofrequency voltage across the ionized gas sufficient to capacitively couple current across the dielectric wall to ablate endometrial tissue. Applying voltage may comprise providing a first electrode in the interior chamber and a second electrode coupled to patient tissue, and applying a radiofrequency voltage across the first and second electrodes. Introducing may comprise, for example, flowing an ionized gas into and out of the interior chamber.





BRIEF DESCRIPTION OF THE DRAWINGS

In order to better understand the invention and to see how it may be carried out in practice, some preferred embodiments are next described, by way of non-limiting examples only, with reference to the accompanying drawings, in which like reference characters denote corresponding features consistently throughout similar embodiments in the attached drawings.



FIG. 1 is a perspective view of an ablation system corresponding to the invention, including a hand-held electrosurgical device for endometrial ablation, RF power source, gas source and controller.



FIG. 2 is a view of the hand-held electrosurgical device of FIG. 1 with a deployed, expanded thin-wall dielectric structure.



FIG. 3 is a block diagram of components of one electrosurgical system corresponding to the invention.



FIG. 4 is a block diagram of the gas flow components of the electrosurgical system of FIG. 1.



FIG. 5 is an enlarged perspective view of the expanded thin-wall dielectric structure, showing an expandable-collapsible frame with the thin dielectric wall in phantom view.



FIG. 6 is a partial sectional view of the expanded thin-wall dielectric structure of FIG. 5 showing (i) translatable members of the expandable-collapsible frame a that move the structure between collapsed and (ii) gas inflow and outflow lumens.



FIG. 7 is a sectional view of an introducer sleeve showing various lumens of the introducer sleeve taken along line 7-7 of FIG. 6.



FIG. 8A is an enlarged schematic view of an aspect of a method of the invention illustrating the step introducing an introducer sleeve into a patient's uterus.



FIG. 8B is a schematic view of a subsequent step of retracting the introducer sleeve to expose a collapsed thin-wall dielectric structure and internal frame in the uterine cavity.



FIG. 8C is a schematic view of subsequent steps of the method, including, (i) actuating the internal frame to move the a collapsed thin-wall dielectric structure to an expanded configuration, (ii) inflating a cervical-sealing balloon carried on the introducer sleeve, and (iii) actuating gas flows and applying RF energy to contemporaneously ionize the gas in the interior chamber and cause capacitive coupling of current through the thin-wall dielectric structure to cause ohmic heating in the engaged tissue indicated by current flow paths.



FIG. 8D is a schematic view of a subsequent steps of the method, including: (i) advancing the introducer sleeve over the thin-wall dielectric structure to collapse it into an interior bore shown in phantom view, and (ii) withdrawing the introducer sleeve and dielectric structure from the uterine cavity.



FIG. 9 is a cut-away perspective view of an alternative expanded thin-wall dielectric structure similar to that of FIGS. 5 and 6 show an alternative electrode configuration.



FIG. 10 is an enlarged cut-away view of a portion of the expanded thin-wall dielectric structure of FIG. 9 showing the electrode configuration.





DETAILED DESCRIPTION OF THE INVENTION

In general, an electrosurgical ablation system is described herein that comprises an elongated introducer member for accessing a patient's uterine cavity with a working end that deploys an expandable thin-wall dielectric structure containing an electrically non-conductive gas as a dielectric. In one embodiment, an interior chamber of the thin-wall dielectric structure contains a circulating neutral gas such as argon. An RF power source provides current that is coupled to the neutral gas flow by a first polarity electrode disposed within the interior chamber and a second polarity electrode at an exterior of the working end. The gas flow, which is converted to a conductive plasma by an electrode arrangement, functions as a switching mechanism that permits current flow to engaged endometrial tissue only when the voltage across the combination of the gas, the thin-wall dielectric structure and the engaged tissue reaches a threshold that causes capacitive coupling across the thin-wall dielectric material. By capacitively coupling current to tissue in this manner, the system provides a substantially uniform tissue effect within all tissue in contact with the expanded dielectric structure. Further, the invention allows the neutral gas to be created contemporaneously with the capacitive coupling of current to tissue.


In general, this disclosure may use the terms “plasma”, “conductive gas” and “ionized gas” interchangeably. A plasma consists of a state of matter in which electrons in a neutral gas are stripped or “ionized” from their molecules or atoms. Such plasmas can be formed by application of an electric field or by high temperatures. In a neutral gas, electrical conductivity is non-existent or very low. Neutral gases act as a dielectric or insulator until the electric field reaches a breakdown value, freeing the electrons from the atoms in an avalanche process thus forming a plasma. Such a plasma provides mobile electrons and positive ions, and acts as a conductor which supports electric currents and can form spark or arc. Due to their lower mass, the electrons in a plasma accelerate more quickly in response to an electric field than the heavier positive ions, and hence carry the bulk of the current.



FIG. 1 depicts one embodiment of an electrosurgical ablation system 100 configured for endometrial ablation. The system 100 includes a hand-held apparatus 105 with a proximal handle 106 shaped for grasping with a human hand that is coupled to an elongated introducer sleeve 110 having axis 111 that extends to a distal end 112. The introducer sleeve 110 can be fabricated of a thin-wall plastic, composite, ceramic or metal in a round or oval cross-section having a diameter or major axis ranging from about 4 mm to 8 mm in at least a distal portion of the sleeve that accesses the uterine cavity. The handle 106 is fabricated of an electrically insulative material such as a molded plastic with a pistol-grip having first and second portions, 114a and 114b, that can be squeezed toward one another to translate an elongated translatable sleeve 115 which is housed in a bore 120 in the elongated introducer sleeve 110. By actuating the first and second handle portions, 114a and 114b, a working end 122 can be deployed from a first retracted position (FIG. 1) in the distal portion of bore 120 in introducer sleeve 110 to an extended position as shown in FIG. 2. In FIG. 2, it can be seen that the first and second handle portions, 114a and 114b, are in a second actuated position with the working end 122 deployed from the bore 120 in introducer sleeve 110.



FIGS. 2 and 3 shows that ablation system 100 includes an RF energy source 130A and RF controller 130B in a control unit 135. The RF energy source 130A is connected to the hand-held device 105 by a flexible conduit 136 with a plug-in connector 137 configured with a gas inflow channel, a gas outflow channel, and first and second electrical leads for connecting to receiving connector 138 in the control unit 135. The control unit 135, as will be described further below in FIGS. 3 and 4, further comprises a neutral gas inflow source 140A, gas flow controller 140B and optional vacuum or negative pressure source 145 to provide controlled gas inflows and gas outflows to and from the working end 122. The control unit 135 further includes a balloon inflation source 148 for inflating an expandable sealing balloon 225 carried on introducer sleeve 110 as described further below.


Referring to FIG. 2, the working end 122 includes a flexible, thin-wall member or structure 150 of a dielectric material that when expanded has a triangular shape configured for contacting the patient's endometrial lining that is targeted for ablation. In one embodiment as shown in FIGS. 2, 5 and 6, the dielectric structure 150 comprises a thin-wall material such as silicone with a fluid-tight interior chamber 152.


In an embodiment, an expandable-collapsible frame assembly 155 is disposed in the interior chamber. Alternatively, the dielectric structure may be expanded by a neutral gas without a frame, but using a frame offers a number of advantages. First, the uterine cavity is flattened with the opposing walls in contact with one another. Expanding a balloon-type member may cause undesirable pain or spasms. For this reason, a flat structure that is expanded by a frame is better suited for deployment in the uterine cavity. Second, in embodiments herein, the neutral gas is converted to a conductive plasma at a very low pressure controlled by gas inflows and gas outflows—so that any pressurization of a balloon-type member with the neutral gas may exceed a desired pressure range and would require complex controls of gas inflows and gas outflows. Third, as described below, the frame provides an electrode for contact with the neutral gas in the interior chamber 152 of the dielectric structure 150, and the frame 155 extends into all regions of the interior chamber to insure electrode exposure to all regions of the neutral gas and plasma. The frame 155 can be constructed of any flexible material with at least portions of the frame functioning as spring elements to move the thin-wall structure 150 from a collapsed configuration (FIG. 1) to an expanded, deployed configuration (FIG. 2) in a patient's uterine cavity. In one embodiment, the frame 155 comprises stainless steel elements 158a, 158b and 160a and 160b that function akin to leaf springs. The frame can be a stainless steel such as 316 SS, 17A SS, 420 SS, 440 SS or the frame can be a NiTi material. The frame preferably extends along a single plane, yet remains thin transverse to the plane, so that the frame may expand into the uterine cavity. The frame elements can have a thickness ranging from about 0.005″ to 0.025″. As can be seen in FIGS. 5 and 6, the proximal ends 162a and 162b of spring elements 158a, 158b are fixed (e.g., by welds 164) to the distal end 165 of sleeve member 115. The proximal ends 166a and 166b of spring elements 160a, 160b are welded to distal portion 168 of a secondary translatable sleeve 170 that can be extended from bore 175 in translatable sleeve 115. The secondary translatable sleeve 170 is dimensioned for a loose fit in bore 175 to allow gas flows within bore 175. FIGS. 5 and 6 further illustrate the distal ends 176a and 176b of spring elements 158a, 158b are welded to distal ends 178a and 178b of spring elements 160a and 160b to thus provide a frame 155 that can be moved from a linear shape (see FIG. 1) to an expanded triangular shape (FIGS. 5 and 6).


As will be described further below, the bore 175 in sleeve 115 and bore 180 in secondary translatable sleeve 170 function as gas outflow and gas inflow lumens, respectively. It should be appreciated that the gas inflow lumen can comprise any single lumen or plurality of lumens in either sleeve 115 or sleeve 170 or another sleeve, or other parts of the frame 155 or the at least one gas flow lumen can be formed into a wall of dielectric structure 150. In FIGS. 5, 6 and 7 it can be seen that gas inflows are provided through bore 180 in sleeve 170, and gas outflows are provided in bore 175 of sleeve 115. However, the inflows and outflows can be also be reversed between bores 175 and 180 of the various sleeves. FIGS. 5 and 6 further show that a rounded bumper element 185 is provided at the distal end of sleeve 170 to insure that no sharp edges of the distal end of sleeve 170 can contact the inside of the thin dielectric wall 150. In one embodiment, the bumper element 185 is silicone, but it could also comprise a rounded metal element. FIGS. 5 and 6 also show that a plurality of gas inflow ports 188 can be provided along a length of in sleeve 170 in chamber 152, as well as a port 190 in the distal end of sleeve 170 and bumper element 185. The sectional view of FIG. 7 also shows the gas flow passageways within the interior of introducer sleeve 110.


It can be understood from FIGS. 1, 2, 5 and 6 that actuation of first and second handle portions, 114a and 114b, (i) initially causes movement of the assembly of sleeves 115 and 170 relative to bore 120 of introducer sleeve 110, and (ii) secondarily causes extension of sleeve 170 from bore 175 in sleeve 115 to expand the frame 155 into the triangular shape of FIG. 5. The dimensions of the triangular shape are suited for a patient uterine cavity, and for example can have an axial length A ranging from 4 to 10 cm and a maximum width B at the distal end ranging from about 2 to 5 cm. In one embodiment, the thickness C of the thin-wall structure 150 can be from 1 to 4 mm as determined by the dimensions of spring elements 158a, 158b, 160a and 160b of frame assembly 155. It should be appreciated that the frame assembly 155 can comprise round wire elements, flat spring elements, of any suitable metal or polymer that can provide opening forces to move thin-wall structure 150 from a collapsed configuration to an expanded configuration within the patient uterus. Alternatively, some elements of the frame 155 can be spring elements and some elements can be flexible without inherent spring characteristics.


As will be described below, the working end embodiment of FIGS. 2, 5 and 6 has a thin-wall structure 150 that is formed of a dielectric material such as silicone that permits capacitive coupling of current to engaged tissue while the frame assembly 155 provides structural support to position the thin-wall structure 150 against tissue. Further, gas inflows into the interior chamber 152 of the thin-wall structure can assist in supporting the dielectric wall so as to contact endometrial tissue. The dielectric thin-wall structure 150 can be free from fixation to the frame assembly 155, or can be bonded to an outward-facing portion or portions of frame elements 158a and 158b. The proximal end 182 of thin-wall structure 150 is bonded to the exterior of the distal end of sleeve 115 to thus provide a sealed, fluid-tight interior chamber 152 (FIG. 5).


In one embodiment, the gas inflow source 140A comprises one or more compressed gas cartridges that communicate with flexible conduit 136 through plug-in connector 137 and receiving connector 138 in the control unit 135 (FIGS. 1-2). As can be seen in FIGS. 5-6, the gas inflows from source 140A flow through bore 180 in sleeve 170 to open terminations 188 and 190 therein to flow into interior chamber 152. A vacuum source 145 is connected through conduit 136 and connector 137 to allow circulation of gas flow through the interior chamber 152 of the thin-wall dielectric structure 150. In FIGS. 5 and 6, it can be seen that gas outflows communicate with vacuum source 145 through open end 200 of bore 175 in sleeve 115. Referring to FIG. 5, it can be seen that frame elements 158a and 158b are configured with a plurality of apertures 202 to allow for gas flows through all interior portions of the frame elements, and thus gas inflows from open terminations 188, 190 in bore 180 are free to circulated through interior chamber 152 to return to an outflow path through open end 200 of bore 175 of sleeve 115. As will be described below (see FIGS. 3-4), the gas inflow source 140A is connected to a gas flow or circulation controller 140B which controls a pressure regulator 205 and also controls vacuum source 145 which is adapted for assisting in circulation of the gas. It should be appreciated that the frame elements can be configured with apertures, notched edges or any other configurations that allow for effective circulation of a gas through interior chamber 152 of the thin-wall structure 150 between the inflow and outflow passageways.


Now turning to the electrosurgical aspects of the invention, FIGS. 5 and 6 illustrate opposing polarity electrodes of the system 100 that are configured to convert a flow of neutral gas in chamber 152 into a plasma 208 (FIG. 6) and to allow capacitive coupling of current through a wall 210 of the thin-wall dielectric structure 150 to endometrial tissue in contact with the wall 210. The electrosurgical methods of capacitively coupling RF current across a plasma 208 and dielectric wall 210 are described in U.S. patent application Ser. No. 12/541,043; filed Aug. 13, 2009 and U.S. application Ser. No. 12/541,050, referenced above. In FIGS. 5 and 6, the first polarity electrode 215 is within interior chamber 152 to contact the neutral gas flow and comprises the frame assembly 155 that is fabricated of an electrically conductive stainless steel. In another embodiment, the first polarity electrode can be any element disposed within the interior chamber 152, or extendable into interior chamber 152. The first polarity electrode 215 is electrically coupled to sleeves 115 and 170 which extends through the introducer sleeve 110 to handle 106 and conduit 136 and is connected to a first pole of the RF source energy source 130A and controller 130B. A second polarity electrode 220 is external of the internal chamber 152 and in one embodiment the electrode is spaced apart from wall 210 of the thin-wall dielectric structure 150. In one embodiment as depicted in FIGS. 5 and 6, the second polarity electrode 220 comprises a surface element of an expandable balloon member 225 carried by introducer sleeve 110. The second polarity electrode 220 is coupled by a lead (not shown) that extends through the introducer sleeve 110 and conduit 136 to a second pole of the RF source 130A. It should be appreciated that second polarity electrode 220 can be positioned on sleeve 110 or can be attached to surface portions of the expandable thin-wall dielectric structure 150, as will be described below, to provide suitable contact with body tissue to allow the electrosurgical ablation of the method of the invention. The second polarity electrode 220 can comprise a thin conductive metallic film, thin metal wires, a conductive flexible polymer or a polymeric positive temperature coefficient material. In one embodiment depicted in FIGS. 5 and 6, the expandable member 225 comprises a thin-wall compliant balloon having a length of about 1 cm to 6 cm that can be expanded to seal the cervical canal. The balloon 225 can be inflated with a gas or liquid by any inflation source 148, and can comprise a syringe mechanism controlled manually or by control unit 135. The balloon inflation source 148 is in fluid communication with an inflation lumen 228 in introducer sleeve 110 that extends to an inflation chamber of balloon 225 (see FIG. 7).


Referring back to FIG. 1, the control unit 135 can include a display 230 and touchscreen or other controls 232 for setting and controlling operational parameters such as treatment time intervals, treatment algorithms, gas flows, power levels and the like. Suitable gases for use in the system include argon, other noble gases and mixtures thereof. In one embodiment, a footswitch 235 is coupled to the control unit 135 for actuating the system.


The box diagrams of FIGS. 3 and 4 schematically depict the system 100, subsystems and components that are configured for an endometrial ablation system. In the box diagram of FIG. 3, it can be seen that RF energy source 130A and circuitry is controlled by a controller 130B. The system can include feedback control systems that include signals relating to operating parameters of the plasma in interior chamber 152 of the dielectric structure 150. For example, feedback signals can be provided from at least one temperature sensor 240 in the interior chamber 152 of the dielectric structure 150, from a pressure sensor within, or in communication, with interior chamber 152, and/or from a gas flow rate sensor in an inflow or outflow channel of the system. FIG. 4 is a schematic block diagram of the flow control components relating to the flow of gas media through the system 100 and hand-held device 105. It can be seen that a pressurized gas source 140A is linked to a downstream pressure regulator 205, an inflow proportional valve 246, flow meter 248 and normally closed solenoid valve 250. The valve 250 is actuated by the system operator which then allows a flow of a neutral gas from gas source 140A to circulate through flexible conduit 136 and the device 105. The gas outflow side of the system includes a normally open solenoid valve 260, outflow proportional valve 262 and flowmeter 264 that communicate with vacuum pump or source 145. The gas can be exhausted into the environment or into a containment system. A temperature sensor 270 (e.g., thermocouple) is shown in FIG. 4 that is configured for monitoring the temperature of outflow gases. FIG. 4 further depicts an optional subsystem 275 which comprises a vacuum source 280 and solenoid valve 285 coupled to the controller 140B for suctioning steam from a uterine cavity 302 at an exterior of the dielectric structure 150 during a treatment interval. As can be understood from FIG. 4, the flow passageway from the uterine cavity 302 can be through bore 120 in sleeve 110 (see FIGS. 2, 6 and 7) or another lumen in a wall of sleeve 110 can be provided.



FIGS. 8A-8D schematically illustrate a method of the invention wherein (i) the thin-wall dielectric structure 150 is deployed within a patient uterus and (ii) RF current is applied to a contained neutral gas volume in the interior chamber 152 to contemporaneously create a plasma 208 in the chamber and capacitively couple current through the thin dielectric wall 210 to apply ablative energy to the endometrial lining to accomplish global endometrial ablation.


More in particular, FIG. 8A illustrates a patient uterus 300 with uterine cavity 302 surrounded by endometrium 306 and myometrium 310. The external cervical os 312 is the opening of the cervix 314 into the vagina 316. The internal os or opening 320 is a region of the cervical canal that opens to the uterine cavity 302. FIG. 8A depicts a first step of a method of the invention wherein the physician has introduced a distal portion of sleeve 110 into the uterine cavity 302. The physician gently can advance the sleeve 110 until its distal tip contacts the fundus 324 of the uterus. Prior to insertion of the device, the physician can optionally introduce a sounding instrument into the uterine cavity to determine uterine dimensions, for example from the internal os 320 to fundus 324.



FIG. 8B illustrates a subsequent step of a method of the invention wherein the physician begins to actuate the first and second handle portions, 114a and 114b, and the introducer sleeve 110 retracts in the proximal direction to expose the collapsed frame 155 and thin-wall structure 150 within the uterine cavity 302. The sleeve 110 can be retracted to expose a selected axial length of thin-wall dielectric structure 150, which can be determined by markings 330 on sleeve 115 (see FIG. 1) which indicate the axial travel of sleeve 115 relative to sleeve 170 and thus directly related to the length of deployed thin-wall structure 150. FIG. 2 depicts the handle portions 114a and 114b fully approximated thus deploying the thin-wall structure to its maximum length.



FIG. 8C illustrates several subsequent steps of a method of the invention. FIG. 8C first depicts the physician continuing to actuate the first and second handle portions, 114a and 114b, which further actuates the frame 155 (see FIGS. 5-6) to expand the frame 155 and thin-wall structure 150 to a deployed triangular shape to contact the patient's endometrial lining 306. The physician can slightly rotate and move the expanding dielectric structure 150 back and forth as the structure is opened to insure it is opened to the desired extent. In performing this step, the physician can actuate handle portions, 114a and 114b, a selected degree which causes a select length of travel of sleeve 170 relative to sleeve 115 which in turn opens the frame 155 to a selected degree. The selected actuation of sleeve 170 relative to sleeve 115 also controls the length of dielectric structure deployed from sleeve 110 into the uterine cavity. Thus, the thin-wall structure 150 can be deployed in the uterine cavity with a selected length, and the spring force of the elements of frame 155 will open the structure 150 to a selected triangular shape to contact or engage the endometrium 306. In one embodiment, the expandable thin-wall structure 150 is urged toward and maintained in an open position by the spring force of elements of the frame 155. In the embodiment depicted in FIGS. 1 and 2, the handle 106 includes a locking mechanism with finger-actuated sliders 332 on either side of the handle that engage a grip-lock element against a notch in housing 333 coupled to introducer sleeve 110 (FIG. 2) to lock sleeves 115 and 170 relative to introducer sleeve 110 to maintain the thin-wall dielectric structure 150 in the selected open position.



FIG. 8C further illustrates the physician expanding the expandable balloon structure 225 from inflation source 148 to thus provide an elongated sealing member to seal the cervix 314 outward from the internal os 320. Following deployment of the thin-wall structure 150 and balloon 225 in the cervix 314, the system 100 is ready for the application of RF energy to ablate endometrial tissue 306. FIG. 8C next depicts the actuation of the system 100, for example, by actuating footswitch 235, which commences a flow of neutral gas from source 140A into the interior chamber 152 of the thin-wall dielectric structure 150. Contemporaneous with, or after a selected delay, the system's actuation delivers RF energy to the electrode arrangement which includes first polarity electrode 215 (+) of frame 155 and the second polarity electrode 220 (−) which is carried on the surface of expandable balloon member 225. The delivery of RF energy delivery will instantly convert the neutral gas in interior chamber 152 into conductive plasma 208 which in turn results in capacitive coupling of current through the dielectric wall 210 of the thin-wall structure 150 resulting in ohmic heating of the engaged tissue. FIG. 8C schematically illustrates the multiplicity of RF current paths 350 between the plasma 208 and the second polarity electrode 220 through the dielectric wall 210. By this method, it has been found that ablation depths of three mm to six mm or more can be accomplished very rapidly, for example in 60 seconds to 120 seconds dependent upon the selected voltage and other operating parameters. In operation, the voltage at which the neutral gas inflow, such as argon, becomes conductive (i.e., converted in part into a plasma) is dependent upon a number of factors controlled by the controllers 130B and 140B, including the pressure of the neutral gas, the volume of interior chamber 152, the flow rate of the gas through the chamber 152, the distance between electrode 210 and interior surfaces of the dielectric wall 210, the dielectric constant of the dielectric wall 210 and the selected voltage applied by the RF source 130, all of which can be optimized by experimentation. In one embodiment, the gas flow rate can be in the range of 5 ml/sec to 50 ml/sec. The dielectric wall 210 can comprise a silicone material having a thickness ranging from a 0.005″ to 0.015 and having a relative permittivity in the range of 3 to 4. The gas can be argon supplied in a pressurized cartridge which is commercially available. Pressure in the interior chamber 152 of dielectric structure 150 can be maintained between 14 psia and 15 psia with zero or negative differential pressure between gas inflow source 140A and negative pressure or vacuum source 145. The controller is configured to maintain the pressure in interior chamber in a range that varies by less than 10% or less than 5% from a target pressure. The RF power source 130A can have a frequency of 450 to 550 KHz, and electrical power can be provided within the range of 600 Vrms to about 1200 Vrms and about 0.2 Amps to 0.4 Amps and an effective power of 40 W to 100 W. In one method, the control unit 135 can be programmed to delivery RF energy for a preselected time interval, for example, between 60 seconds and 120 seconds. One aspect of a treatment method corresponding to the invention consists of ablating endometrial tissue with RF energy to elevate endometrial tissue to a temperature greater than 45 degrees Celsius for a time interval sufficient to ablate tissue to a depth of at least 1 mm. Another aspect of the method of endometrial ablation of consists of applying radiofrequency energy to elevate endometrial tissue to a temperature greater than 45 degrees Celsius without damaging the myometrium.



FIG. 8D illustrates a final step of the method wherein the physician deflates the expandable balloon member 225 and then extends sleeve 110 distally by actuating the handles 114a and 114b to collapse frame 155 and then retracting the assembly from the uterine cavity 302. Alternatively, the deployed working end 122 as shown in FIG. 8C can be withdrawn in the proximal direction from the uterine cavity wherein the frame 155 and thin-wall structure 150 will collapse as it is pulled through the cervix. FIG. 8D shows the completed ablation with the ablated endometrial tissue indicated at 360.


In another embodiment, the system can include an electrode arrangement in the handle 106 or within the gas inflow channel to pre-ionize the neutral gas flow before it reaches the interior chamber 152. For example, the gas inflow channel can be configured with axially or radially spaced apart opposing polarity electrodes configured to ionize the gas inflow. Such electrodes would be connected in separate circuitry to an RF source. The first and second electrodes 215 (+) and 220 (−) described above would operate as described above to provide the current that is capacitively coupled to tissue through the walls of the dielectric structure 150. In all other respects, the system and method would function as described above.


Now turning to FIGS. 9 and 10, an alternate working end 122 with thin-wall dielectric structure 150 is shown. In this embodiment, the thin-wall dielectric structure 150 is similar to that of FIGS. 5 and 6 except that the second polarity electrode 220′ that is exterior of the internal chamber 152 is disposed on a surface portion 370 of the thin-wall dielectric structure 150. In this embodiment, the second polarity electrode 220′ comprises a thin-film conductive material, such as gold, that is bonded to the exterior of thin-wall material 210 along two lateral sides 354 of dielectric structure 150. It should be appreciated that the second polarity electrode can comprise one or more conductive elements disposed on the exterior of wall material 210, and can extend axially, or transversely to axis 111 and can be singular or multiple elements. In one embodiment shown in more detail in FIG. 10, the second polarity electrode 220′ can be fixed on another lubricious layer 360, such as a polyimide film, for example KAPTON®. The polyimide tape extends about the lateral sides 354 of the dielectric structure 150 and provides protection to the wall 210 when it is advanced from or withdrawn into bore 120 in sleeve 110. In operation, the RF delivery method using the embodiment of FIGS. 9 and 10 is the same as described above, with RF current being capacitively coupled from the plasma 208 through the wall 210 and endometrial tissue to the second polarity electrode 220′ to cause the ablation.



FIG. 9 further shows an optional temperature sensor 390, such as a thermocouple, carried at an exterior of the dielectric structure 150. In one method of use, the control unit 135 can acquire temperature feedback signals from at least one temperature sensor 390 to modulate or terminate RF energy delivery, or to modulate gas flows within the system. In a related method of the invention, the control unit 135 can acquire temperature feedback signals from temperature sensor 240 in interior chamber 152 (FIG. 6 to modulate or terminate RF energy delivery or to modulate gas flows within the system.


Although particular embodiments of the present invention have been described above in detail, it will be understood that this description is merely for purposes of illustration and the above description of the invention is not exhaustive. Specific features of the invention are shown in some drawings and not in others, and this is for convenience only and any feature may be combined with another in accordance with the invention. A number of variations and alternatives will be apparent to one having ordinary skills in the art. Such alternatives and variations are intended to be included within the scope of the claims. Particular features that are presented in dependent claims can be combined and fall within the scope of the invention. The invention also encompasses embodiments as if dependent claims were alternatively written in a multiple dependent claim format with reference to other independent claims.

Claims
  • 1. A method for delivering radiofrequency current to endometrial tissue, comprising: deploying a triangular dielectric wall surrounding an interior chamber in a patient's uterus;providing an electrically conductive plasma in the interior chamber of the dielectric wall;capacitively coupling a radiofrequency current through the plasma and across the dielectric wall into the endometrial tissue;wherein providing the electrically conductive plasma comprises converting a neutral gas into the electrically conductive plasma;wherein converting the neutral gas into the electrically conductive plasma comprises flowing the neutral gas into the interior chamber; andwherein radiofrequency current is capacitively coupled to the neutral gas by a first polarity electrode within the interior chamber.
  • 2. The method of claim 1, further comprising a second polarity electrode disposed proximate to the dielectric wall and exterior to the interior chamber, the second polarity electrode configured to capacitively couple radiofrequency current to the neutral gas and the first polarity electrode.
  • 3. The method of claim 1, further comprising modulating the radiofrequency current in response to a signal provided by a temperature sensor external of the interior chamber.
  • 4. The method of claim 1, wherein the capacitively coupling of the radiofrequency current to endometrial tissue generates plasma filaments.
  • 5. The method of claim 1, wherein dielectric material of the dielectric wall momentarily concentrates electrostatic lines of flux, allowing radiofrequency current to pass across the dielectric wall to the endometrial tissue.
  • 6. The method of claim 1, wherein the radiofrequency current is delivered at a frequency between 480 kHz and 500 kHz.
  • 7. The method of claim 1, wherein the dielectric wall is in contact with the endometrial tissue.
  • 8. A method for delivering radiofrequency current to endometrial tissue, comprising: deploying a triangular dielectric wall surrounding an interior chamber in a patient's uterus, a first polarity electrode located within the interior chamber, and a second polarity electrode located exterior of the interior chamber;converting a neutral gas into an electrically conductive plasma in the interior chamber of the dielectric wall by applying a radiofrequency current within the interior chamber;capacitively coupling the radiofrequency current through the plasma and across the dielectric wall into the endometrial tissue.
  • 9. The method of claim 8, wherein the first and second polarity electrodes are configured to capacitively couple radiofrequency current to the neutral gas to create the electrically conductive plasma.
  • 10. The method of claim 8, wherein the dielectric wall is comprised of silicone having a wall thickness to permit capacitive coupling of electrical current therethrough.
  • 11. The method of claim 8, wherein converting the neutral gas into the electrically conductive plasma comprises flowing the neutral gas into the interior chamber.
  • 12. A method for delivering radiofrequency current to endometrial tissue, comprising: transcervical inserting a device into a patient's uterus;deploying a dielectric wall at a distal end of the device in the uterus, the dielectric wall surrounding an interior chamber;converting a neutral gas into an electrically conductive plasma in the interior chamber of the dielectric wall by applying a radiofrequency current within the interior chamber, the radiofrequency current passing between a first polarity electrode within the interior chamber and a second polarity electrode exterior the interior chamber; andcapacitively coupling the radiofrequency current to pass across the dielectric wall into the endometrial tissue.
  • 13. The method of claim 12, further comprising modulating the radiofrequency current in response to a signal provided by a temperature sensor external of the interior chamber.
  • 14. The method of claim 12, wherein converting the neutral gas into the electrically conductive plasma comprises flowing the neutral gas into the interior chamber.
  • 15. The method of claim 12, wherein capacitive coupling of the radiofrequency current passing across the dielectric wall does not occur until a voltage across the neutral gas reaches a threshold level.
  • 16. The method of claim 12, wherein the dielectric wall is in contact with endometrial tissue in the uterus.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/657,684, filed Mar. 13, 2015 (now U.S. Pat. No. 10,912,606), which is a continuation of U.S. patent application Ser. No. 13/975,139, filed Aug. 23, 2013, (now U.S. Pat. No. 8,998,901) which is a continuation of U.S. patent application Ser. No. 12/605,929, filed Oct. 26, 2009 (now U.S. Pat. No. 8,540,708), which is a continuation in part of U.S. patent application Ser. No. 12/541,043, filed on Aug. 13, 2009 (now U.S. Pat. No. 8,372,068) and U.S. patent application Ser. No. 12/541,050, filed on Aug. 13, 2009, (now U.S. Pat. No. 8,382,753), which claim the benefit of Provisional Application No. 61/196,870, filed on Oct. 21, 2008, the full disclosures of which are incorporated herein by reference.

US Referenced Citations (374)
Number Name Date Kind
3903891 Brayshaw Sep 1975 A
4428748 Peyman et al. Jan 1984 A
4949718 Neuwirth et al. Aug 1990 A
4979948 Geddes et al. Dec 1990 A
4989583 Hood Feb 1991 A
5045056 Behl Sep 1991 A
5078717 Parins et al. Jan 1992 A
5084044 Quint Jan 1992 A
5085659 Rydell et al. Feb 1992 A
5191883 Lennox et al. Mar 1993 A
5197963 Parins Mar 1993 A
5242390 Goldrath Sep 1993 A
5248312 Langberg Sep 1993 A
5269794 Rexroth Dec 1993 A
5277201 Stern Jan 1994 A
5282799 Rydell Feb 1994 A
5324254 Phillips Jun 1994 A
5344435 Turner Sep 1994 A
5374261 Yoon Dec 1994 A
5401272 Perkins Mar 1995 A
5401274 Kusunoki Mar 1995 A
5429136 Milo et al. Jul 1995 A
5441498 Perkins Aug 1995 A
5443470 Stern Aug 1995 A
5456689 Kresch et al. Oct 1995 A
5483994 Maurer Jan 1996 A
5496314 Eggers Mar 1996 A
5501681 Neuwirth et al. Mar 1996 A
5505730 Edwards Apr 1996 A
5507725 Savage et al. Apr 1996 A
5558672 Edwards et al. Sep 1996 A
5562703 Desai Oct 1996 A
5562720 Stern Oct 1996 A
5575788 Baker et al. Nov 1996 A
5584872 Lafontaine et al. Dec 1996 A
5592727 Glowa et al. Jan 1997 A
5622647 Kerr et al. Apr 1997 A
5647848 Jorgensen Jul 1997 A
5653684 Laptewicz et al. Aug 1997 A
5653692 Masterson et al. Aug 1997 A
5662647 Crow et al. Sep 1997 A
5672174 Gough et al. Sep 1997 A
5681308 Edwards et al. Oct 1997 A
5697281 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5713942 Stern et al. Feb 1998 A
5733298 Berman et al. Mar 1998 A
5769846 Edwards et al. Jun 1998 A
5769880 Truckai Jun 1998 A
5779662 Berman Jul 1998 A
5800493 Stevens et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5827273 Edwards Oct 1998 A
5833644 Zadno-Azizi et al. Nov 1998 A
5843020 Tu et al. Dec 1998 A
5846239 Swanson et al. Dec 1998 A
5860974 Abele et al. Jan 1999 A
5866082 Hatton et al. Feb 1999 A
5876340 Tu et al. Mar 1999 A
5879347 Saadat et al. Mar 1999 A
5891094 Masterson et al. Apr 1999 A
5891134 Goble et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5902251 Vanhooydonk May 1999 A
5904651 Swanson et al. May 1999 A
5925038 Panescu et al. Jul 1999 A
5954714 Saadat et al. Sep 1999 A
5958782 Bentsen et al. Sep 1999 A
5964755 Edwards Oct 1999 A
5976129 Desai Nov 1999 A
5980515 Tu Nov 1999 A
5997534 Tu et al. Dec 1999 A
6015406 Goble Jan 2000 A
6024743 Edwards Feb 2000 A
6026331 Feldberg et al. Feb 2000 A
6041260 Stern et al. Mar 2000 A
6053909 Shadduck Apr 2000 A
6057689 Saadat May 2000 A
6066132 Chen May 2000 A
6086581 Reynolds et al. Jul 2000 A
6091993 Bouchier et al. Jul 2000 A
6113597 Eggers et al. Sep 2000 A
6136014 Sirimanne et al. Oct 2000 A
6139570 Saadat et al. Oct 2000 A
6146378 Mikus et al. Nov 2000 A
6149620 Baker Nov 2000 A
6214003 Morgan et al. Apr 2001 B1
6228078 Eggers et al. May 2001 B1
6238392 Long May 2001 B1
6254599 Lesh et al. Jul 2001 B1
6283962 Tu et al. Sep 2001 B1
6296639 Truckai et al. Oct 2001 B1
6302904 Wallstén et al. Oct 2001 B1
6315776 Edwards et al. Nov 2001 B1
6366818 Bolmsjo Apr 2002 B1
6387088 Shattuck May 2002 B1
6395012 Yoon et al. May 2002 B1
6409722 Hoey Jun 2002 B1
6416508 Eggers et al. Jul 2002 B1
6416511 Lesh et al. Jul 2002 B1
6443947 Marko Sep 2002 B1
6491690 Goble et al. Dec 2002 B1
6508815 Strul et al. Jan 2003 B1
6551310 Ganz et al. Apr 2003 B1
6565561 Goble et al. May 2003 B1
6582427 Goble Jun 2003 B1
6589237 Woloszko et al. Jul 2003 B2
6602248 Sharps et al. Aug 2003 B1
6607545 Kammerer et al. Aug 2003 B2
6622731 Daniel et al. Sep 2003 B2
6635054 Fjield et al. Oct 2003 B2
6635055 Cronin Oct 2003 B1
6663626 Truckai et al. Dec 2003 B2
6673071 Vandusseldorp et al. Jan 2004 B2
6699241 Rappaport et al. Mar 2004 B2
6726684 Woloszko et al. Apr 2004 B1
6736811 Panescu et al. May 2004 B2
6746447 Davison et al. Jun 2004 B2
6758847 Maguire Jul 2004 B2
6780178 Palanker et al. Aug 2004 B2
6802839 Behl Oct 2004 B2
6813520 Truckai et al. Nov 2004 B2
6814730 Li Nov 2004 B2
6832996 Woloszko et al. Dec 2004 B2
6837887 Woloszko et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6840935 Lee Jan 2005 B2
6872205 Lesh et al. Mar 2005 B2
6896674 Woloszko et al. May 2005 B1
6905497 Truckai Jun 2005 B2
6923805 Lafontaine et al. Aug 2005 B1
6929642 Xiao et al. Aug 2005 B2
6949096 Davison et al. Sep 2005 B2
6951569 Nohilly et al. Oct 2005 B2
6954977 Maguire et al. Oct 2005 B2
6960203 Xiao et al. Nov 2005 B2
7074217 Strul et al. Jul 2006 B2
7083614 Fjield et al. Aug 2006 B2
7087052 Sampson et al. Aug 2006 B2
7108696 Daniel et al. Sep 2006 B2
7118590 Cronin Oct 2006 B1
7150747 McDonald et al. Dec 2006 B1
7175734 Stewart et al. Feb 2007 B2
7179255 Lettice et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7192430 Truckai et al. Mar 2007 B2
7238185 Palanker et al. Jul 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7276063 Davison et al. Oct 2007 B2
7278994 Goble et al. Oct 2007 B2
7294126 Sampson et al. Nov 2007 B2
7297143 Woloszko et al. Nov 2007 B2
7326201 Fjield et al. Feb 2008 B2
7331957 Woloszko et al. Feb 2008 B2
RE40156 Sharps et al. Mar 2008 E
7371231 Rioux May 2008 B2
7371235 Thompson et al. May 2008 B2
7381208 Van Der Walt et al. Jun 2008 B2
7387628 Behl et al. Jun 2008 B1
7390330 Harp Jun 2008 B2
7407502 Strul et al. Aug 2008 B2
7419500 Marko et al. Sep 2008 B2
7452358 Stern et al. Nov 2008 B2
7462178 Woloszko et al. Dec 2008 B2
7500973 Vancelette et al. Mar 2009 B2
7512445 Truckai et al. Mar 2009 B2
7530979 Ganz et al. May 2009 B2
7549987 Shadduck Jun 2009 B2
7556628 Utley et al. Jul 2009 B2
7566333 Van Wyk et al. Jul 2009 B2
7572251 Davison et al. Aug 2009 B1
7604633 Truckai et al. Oct 2009 B2
7625368 Schechter et al. Dec 2009 B2
7674259 Shadduck Mar 2010 B2
7678106 Lee Mar 2010 B2
7708733 Sanders et al. May 2010 B2
7717909 Strul et al. May 2010 B2
7736362 Eberl et al. Jun 2010 B2
7744595 Truckai et al. Jun 2010 B2
7749159 Crowley et al. Jul 2010 B2
7824398 Woloszko et al. Nov 2010 B2
7824405 Woloszko et al. Nov 2010 B2
7846160 Payne et al. Dec 2010 B2
7879034 Woloszko et al. Feb 2011 B2
7918795 Grossman Apr 2011 B2
7985188 Felts Jul 2011 B2
8016843 Escaf Sep 2011 B2
8197476 Truckai Jun 2012 B2
8197477 Truckai Jun 2012 B2
8323280 Germain et al. Dec 2012 B2
8372068 Truckai Feb 2013 B2
8382753 Truckai Feb 2013 B2
8486096 Robertson et al. Jul 2013 B2
8500732 Truckai et al. Aug 2013 B2
8540708 Truckai et al. Sep 2013 B2
8657174 Yates et al. Feb 2014 B2
8690873 Truckai et al. Apr 2014 B2
8728003 Taylor et al. May 2014 B2
8821486 Toth et al. Sep 2014 B2
8998901 Truckai et al. Apr 2015 B2
9204918 Germain et al. Dec 2015 B2
9277954 Germain et al. Mar 2016 B2
9427249 Robertson et al. Aug 2016 B2
9472382 Jacofsky Oct 2016 B2
9510850 Robertson et al. Dec 2016 B2
9510897 Truckai Dec 2016 B2
9585675 Germain et al. Mar 2017 B1
9592085 Germain et al. Mar 2017 B2
9603656 Germain et al. Mar 2017 B1
9649125 Truckai May 2017 B2
9651423 Zhang May 2017 B1
9662163 Toth et al. May 2017 B2
9855675 Germain et al. Jan 2018 B1
9901394 Shadduck et al. Feb 2018 B2
9999466 Germain et al. Jun 2018 B2
10004556 Orczy-Timko et al. Jun 2018 B2
10052149 Germain et al. Aug 2018 B2
10213246 Toth et al. Feb 2019 B2
10492856 Orczy-Timko Dec 2019 B2
10517578 Truckai Dec 2019 B2
10595889 Germain et al. Mar 2020 B2
10617461 Toth et al. Apr 2020 B2
10662939 Orczy-Timko et al. May 2020 B2
10912606 Truckai et al. Feb 2021 B2
11259787 Truckai Mar 2022 B2
20010004444 Haser et al. Jun 2001 A1
20020022836 Goble Feb 2002 A1
20020058933 Christopherson May 2002 A1
20020062142 Knowlton May 2002 A1
20020068934 Edwards et al. Jun 2002 A1
20020082635 Kammerer et al. Jun 2002 A1
20020183742 Carmel et al. Dec 2002 A1
20030060813 Loeb et al. Mar 2003 A1
20030065321 Carmel et al. Apr 2003 A1
20030153905 Edwards et al. Aug 2003 A1
20030153908 Goble et al. Aug 2003 A1
20030171743 Tasto et al. Sep 2003 A1
20030176816 Maguire et al. Sep 2003 A1
20030216725 Woloszko et al. Nov 2003 A1
20030236487 Knowlton et al. Dec 2003 A1
20040002702 Xiao et al. Jan 2004 A1
20040010249 Truckai et al. Jan 2004 A1
20040087936 Stern et al. May 2004 A1
20040092980 Cesarini et al. May 2004 A1
20040215180 Starkebaum et al. Oct 2004 A1
20040215182 Lee Oct 2004 A1
20040215296 Ganz et al. Oct 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20050075630 Truckai et al. Apr 2005 A1
20050145009 Vanderveen et al. Jul 2005 A1
20050165389 Swain et al. Jul 2005 A1
20050182397 Ryan Aug 2005 A1
20050187546 Bek et al. Aug 2005 A1
20050192652 Cioanta Sep 2005 A1
20050240176 Oral et al. Oct 2005 A1
20050251131 Lesh Nov 2005 A1
20060009756 Francischelli et al. Jan 2006 A1
20060052771 Sartor Mar 2006 A1
20060084158 Viol Apr 2006 A1
20060084969 Truckai et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060189971 Tasto et al. Aug 2006 A1
20060189976 Karni et al. Aug 2006 A1
20060200040 Weikel, Jr. et al. Sep 2006 A1
20060224154 Shadduck et al. Oct 2006 A1
20060259025 Dahla Nov 2006 A1
20070021743 Rioux et al. Jan 2007 A1
20070027447 Theroux et al. Feb 2007 A1
20070083192 Welch Apr 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070213704 Truckai et al. Sep 2007 A1
20070276430 Lee et al. Nov 2007 A1
20070282323 Woloszko et al. Dec 2007 A1
20070287996 Rioux Dec 2007 A1
20070288075 Dowlatshahi Dec 2007 A1
20070293853 Truckai et al. Dec 2007 A1
20080045859 Fritsch et al. Feb 2008 A1
20080058797 Rioux Mar 2008 A1
20080091061 Kumar et al. Apr 2008 A1
20080097242 Cai Apr 2008 A1
20080097425 Truckai Apr 2008 A1
20080125765 Berenshteyn et al. May 2008 A1
20080125770 Kleyman May 2008 A1
20080154238 McGuckin Jun 2008 A1
20080183132 Davies et al. Jul 2008 A1
20080208189 Van Wyk et al. Aug 2008 A1
20080221567 Sixto et al. Sep 2008 A1
20080249518 Warnking et al. Oct 2008 A1
20080249533 Godin Oct 2008 A1
20080281317 Gobel et al. Nov 2008 A1
20090048593 Ganz et al. Feb 2009 A1
20090054888 Cronin Feb 2009 A1
20090054892 Rioux et al. Feb 2009 A1
20090076494 Azure Mar 2009 A1
20090105703 Shadduck Apr 2009 A1
20090131927 Kastelein et al. May 2009 A1
20090149846 Hoey et al. Jun 2009 A1
20090163908 Maclean et al. Jun 2009 A1
20090209956 Marion Aug 2009 A1
20090234348 Bruszewski et al. Sep 2009 A1
20090259150 Ostrovsky et al. Oct 2009 A1
20090270899 Carusillo et al. Oct 2009 A1
20090306654 Garbagnati Dec 2009 A1
20100004595 Nguyen et al. Jan 2010 A1
20100036372 Truckai et al. Feb 2010 A1
20100036488 De, Jr. et al. Feb 2010 A1
20100042095 Bigley et al. Feb 2010 A1
20100042097 Newton et al. Feb 2010 A1
20100049190 Long et al. Feb 2010 A1
20100094289 Taylor et al. Apr 2010 A1
20100121319 Chu et al. May 2010 A1
20100125269 Emmons et al. May 2010 A1
20100137855 Berjano et al. Jun 2010 A1
20100137857 Shroff et al. Jun 2010 A1
20100152725 Pearson et al. Jun 2010 A1
20100185191 Carr et al. Jul 2010 A1
20100198214 Layton, Jr. et al. Aug 2010 A1
20100204688 Hoey et al. Aug 2010 A1
20100217245 Prescott Aug 2010 A1
20100217256 Strul et al. Aug 2010 A1
20100228239 Freed Sep 2010 A1
20100228245 Sampson et al. Sep 2010 A1
20100234867 Himes Sep 2010 A1
20100286680 Kleyman Nov 2010 A1
20100286688 Hughett, Sr. et al. Nov 2010 A1
20110004205 Chu et al. Jan 2011 A1
20110046513 Hibner Feb 2011 A1
20110060391 Unetich et al. Mar 2011 A1
20110112524 Stern et al. May 2011 A1
20110196401 Robertson et al. Aug 2011 A1
20110196403 Robertson et al. Aug 2011 A1
20110282340 Toth et al. Nov 2011 A1
20110306968 Beckman et al. Dec 2011 A1
20120041434 Truckai Feb 2012 A1
20120330292 Shadduck et al. Dec 2012 A1
20130090642 Shadduck et al. Apr 2013 A1
20130103021 Germain et al. Apr 2013 A1
20130172870 Germain et al. Jul 2013 A1
20130231652 Germain et al. Sep 2013 A1
20130237780 Beasley et al. Sep 2013 A1
20130267937 Shadduck et al. Oct 2013 A1
20130289558 Reid, Jr. et al. Oct 2013 A1
20130296847 Germain et al. Nov 2013 A1
20130331833 Bloom Dec 2013 A1
20140336632 Toth et al. Nov 2014 A1
20140358077 Oruklu et al. Dec 2014 A1
20150119795 Germain et al. Apr 2015 A1
20150119916 Dietz et al. Apr 2015 A1
20150173827 Bloom et al. Jun 2015 A1
20160066982 Marczyk et al. Mar 2016 A1
20160095615 Orczy-Timko et al. Apr 2016 A1
20160113706 Truckai et al. Apr 2016 A1
20160120443 Margalit May 2016 A1
20160157916 Germain et al. Jun 2016 A1
20160287779 Orczy-Timko et al. Oct 2016 A1
20160346036 Orczy-Timko et al. Dec 2016 A1
20170231681 Toth et al. Aug 2017 A1
20170258519 Germain et al. Sep 2017 A1
20170303990 Benamou et al. Oct 2017 A1
20170348493 Wells et al. Dec 2017 A1
20180001009 Crawford et al. Jan 2018 A1
20180010599 Hernandez et al. Jan 2018 A1
20180147003 Shadduck et al. May 2018 A1
20180326144 Truckai Nov 2018 A1
20180369477 Ding et al. Dec 2018 A1
20190030235 Orczy-Timko et al. Jan 2019 A1
20190192218 Orczy-Timko et al. Jun 2019 A1
20200030527 Toth et al. Jan 2020 A1
20200222104 Toth et al. Jul 2020 A1
20200330085 Truckai Oct 2020 A1
20200405953 Toth Dec 2020 A1
20210038279 Toth et al. Feb 2021 A1
20220142697 Toth et al. May 2022 A9
20220151674 Sharma May 2022 A1
Foreign Referenced Citations (19)
Number Date Country
1977194 Jun 2007 CN
101015474 Aug 2007 CN
101198288 Jun 2008 CN
1236440 Sep 2002 EP
1595507 Nov 2005 EP
2349044 Aug 2011 EP
2493407 Sep 2012 EP
2981222 Feb 2016 EP
2005501597 Jan 2005 JP
WO-0053112 Sep 2000 WO
WO-2005122938 Dec 2005 WO
WO-2006001455 Jan 2006 WO
WO-2008083407 Jul 2008 WO
WO-2010048007 Apr 2010 WO
WO-2011053599 May 2011 WO
WO-2011060301 May 2011 WO
WO-2014165715 Oct 2014 WO
WO-2017127760 Jul 2017 WO
WO-2017185097 Oct 2017 WO
Non-Patent Literature Citations (92)
Entry
Notice of Allowance dated Jan. 26, 2022 for U.S. Appl. No. 16/706,179.
Notice of Allowance dated Oct. 20, 2021 for U.S. Appl. No. 16/706,179.
Office action dated Jan. 25, 2022 for U.S. Appl. No. 16/222,757.
Office action dated Apr. 14, 2022 for U.S. Appl. No. 16/909,599.
Office action dated Apr. 28, 2022 for U.S. Appl. No. 16/435,323.
Office action dated May 2, 2022 for U.S. Appl. No. 16/247,404.
Office Action dated Jun. 10, 2022 for U.S. Appl. No. 16/819,386.
Office action dated Jul. 25, 2022 for U.S. Appl. No. 16/222,757.
U.S. Appl. No. 16/909,599 Notice of Allowance dated Sep. 28, 2022.
Allen-Bradley. AC Braking Basics. Rockwell Automation. Feb. 2001. 4 pages. URL: http://literature.rockwellautomation.com/idc/groups/literature/documents/wp/drives-wp004_-en-p.pdf.
Allen-Bradley. What Is Regeneration? Braking / Regeneration Manual: Regeneration Overview. Revision 1.0. Rockwell Automation. Accessed Apr. 24, 2017. 6 pages. URL: https://www.ab.com/support/abdrives/documentation/techpapers/RegenOverview01.pdf.
European search report and opinion dated Nov. 18, 2016 for EP Application No. 14778196.7.
International search report and written opinion dated May 31, 2017 for PCT/US2017/014456.
International Search Report and Written Opinion dated Jul. 7, 2017 for International PCT Patent Application No. PCT/US2017/029201.
International Search Report and Written Opinion dated Nov. 3, 2017 for International PCT Patent Application No. PCT/US2017/039326.
International Search Report dated Jul. 6, 2016 for PCT/US16/25509.
Notice of Allowance dated Jan. 27, 2017 for U.S. Appl. No. 13/236,471.
Notice of Allowance dated Jan. 27, 2017 for U.S. Appl. No. 14/508,856.
Notice of Allowance dated Aug. 6, 2019 for U.S. Appl. No. 15/008,341.
Notice of allowance dated Aug. 17, 2016 for U.S. Appl. No. 13/281,805.
Notice of allowance dated Sep. 10, 2019 for U.S. Appl. No. 15/488,270.
Notice of allowance dated Oct. 19, 2018 for U.S. Appl. No. 14/341,121.
Notice of allowance dated Oct. 19, 2020 for U.S. Appl. No. 14/657,684.
Notice of allowance dated Nov. 15, 2018 for U.S. Appl. No. 14/341,121.
Notice of allowance dated Nov. 27, 2020 for U.S. Appl. No. 14/657,684.
Notice of Allowance dated Dec. 11, 2019 for U.S. Appl. No. 15/583,712.
Notice of allowance dated Dec. 14, 2017 for U.S. Appl. No. 13/857,068.
Office action dated Jan. 2, 2019 for U.S. Appl. No. 15/008,341.
Office action dated Jan. 29, 2021 for U.S. Appl. No. 15/880,958.
Office action dated Feb. 19, 2019 for U.S. Appl. No. 15/488,270.
Office action dated Mar. 9, 2017 for U.S. Appl. No. 15/091,402.
Office Action dated Mar. 14, 2017 for U.S. Appl. No. 15/410,723.
Office Action dated Apr. 5, 2017 for U.S. Appl. No. 13/857,068.
Office action dated Apr. 16, 2020 for U.S. Appl. No. 14/657,684.
Office Action dated Apr. 18, 2017 for U.S. Appl. No. 14/657,684.
Office Action dated Apr. 22, 2016 for U.S. Appl. No. 14/657,684.
Office action dated May 2, 2019 for U.S. Appl. No. 14/657,684.
Office action dated May 6, 2021 for U.S. Appl. No. 16/247,404.
Office Action dated May 9, 2017 for U.S. Appl. No. 15/410,723.
Office action dated May 22, 2015 for U.S. Appl. No. 14/657,684.
Office action dated May 29, 2019 for U.S. Appl. No. 15/583,712.
Office action dated Jun. 8, 2020 for U.S. Appl. No. 15/880,958.
Office action dated Jun. 15, 2018 for U.S. Appl. No. 14/864,379.
Office action dated Jun. 28, 2018 for U.S. Appl. No. 14/341,121.
Office action dated Jul. 12, 2018 for U.S. Appl. No. 14/657,684.
Office action dated Jul. 28, 2017 for U.S. Appl. No. 15/091,402.
Office Action dated Sep. 30, 2016 for U.S. Appl. No. 15/091,402.
Office action dated Nov. 1, 2018 for U.S. Appl. No. 15/583,712.
Office Action dated Nov. 2, 2016 for U.S. Appl. No. 14/657,684.
Office action dated Nov. 27, 2017 for U.S. Appl. No. 14/341,121.
Office action dated Dec. 5, 2017 for U.S. Appl. No. 14/864,379.
European search report and search opinion dated Apr. 16, 2013 for EP Application No. 09822443.
European search report and search opinion dated Jul. 10, 2013 for EP Application No. 10827399.
International search report and written opinion dated Feb. 2, 2011 for PCT/US2010/056591.
International search report and written opinion dated Dec. 10, 2009 for PCT/US2009/060703.
International search report and written opinion dated Dec. 14, 2010 for PCT/US2010/054150.
International Search Report dated Sep. 10, 2014 for PCT/US2014/032895.
Notice of allowance dated Jan. 9, 2014 for U.S. Appl. No. 13/938,032.
Notice of allowance dated Feb. 25, 2015 for U.S. Appl. No. 13/975,139.
Notice of allowance dated Mar. 5, 2012 for U.S. Appl. No. 13/281,846.
Notice of allowance dated Mar. 5, 2012 for U.S. Appl. No. 13/281,856.
Notice of allowance dated Mar. 29, 2013 for U.S. Appl. No. 12/605,546.
Notice of allowance dated May 9, 2014 for U.S. Appl. No. 12/944,466.
Notice of allowance dated May 24, 2013 for U.S. Appl. No. 12/605,929.
Notice of Allowance dated Aug. 2, 2016 for U.S. Appl. No. 13/281,805.
Notice of allowance dated Nov. 15, 2012 for U.S. Appl. No. 12/541,043.
Notice of allowance dated Nov. 15, 2012 for U.S. Appl. No. 12/541,050.
Notice of allowance dated Dec. 2, 2014 for U.S. Appl. No. 13/975,139.
Office action dated Jan. 28, 2013 for U.S. Appl. No. 12/605,546.
Office action dated Feb. 4, 2016 for U.S. Appl. No. 13/857,068.
Office action dated Mar. 12, 2012 for U.S. Appl. No. 12/541,043.
Office action dated Mar. 12, 2012 for U.S. Appl. No. 12/541,050.
Office Action dated Mar. 31, 2016 for U.S. Appl. No. 13/281,805.
Office action dated Apr. 24, 2014 for U.S. Appl. No. 13/975,139.
Office action dated Jun. 5, 2015 for U.S. Appl. No. 13/857,068.
Office action dated Jun. 18, 2012 for U.S. Appl. No. 12/605,546.
Office Action dated Jun. 29, 2016 for U.S. Appl. No. 14/508,856.
Office Action dated Jul. 5, 2016 for U.S. Appl. No. 13/236,471.
Office action dated Jul. 23, 2015 for U.S. Appl. No. 13/281,805.
Office Action dated Sep. 7, 2016 for U.S. Appl. No. 13/857,068.
Office action dated Sep. 22, 2014 for U.S. Appl. No. 13/281,805.
Office action dated Sep. 24, 2015 for U.S. Appl. No. 13/236,471.
Office action dated Sep. 28, 2012 for U.S. Appl. No. 12/541,043.
Office action dated Sep. 28, 2012 for U.S. Appl. No. 12/541,050.
Office action dated Sep. 28, 2012 for U.S. Appl. No. 12/605,929.
Office action dated Oct. 9, 2014 for U.S. Appl. No. 13/857,068.
Office action dated Oct. 24, 2014 for U.S. Appl. No. 13/975,139.
Office action dated Nov. 6, 2013 for U.S. Appl. No. 13/938,032.
Office action dated Dec. 4, 2014 for U.S. Appl. No. 13/236,471.
Office action dated Dec. 6, 2011 for U.S. Appl. No. 13/281,846.
Office action dated Dec. 16, 2014 for U.S. Appl. No. 13/281,805.
Office action dated Dec. 22, 2011 for U.S. Appl. No. 13/281,856.
Related Publications (1)
Number Date Country
20210346087 A1 Nov 2021 US
Provisional Applications (1)
Number Date Country
61196870 Oct 2008 US
Continuations (3)
Number Date Country
Parent 14657684 Mar 2015 US
Child 17149516 US
Parent 13975139 Aug 2013 US
Child 14657684 US
Parent 12605929 Oct 2009 US
Child 13975139 US
Continuation in Parts (2)
Number Date Country
Parent 12541050 Aug 2009 US
Child 12605929 US
Parent 12541043 Aug 2009 US
Child 12605929 US